Kymera Therapeutics Inc (KYMR) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Kymera Therapeutics Inc   (NASDAQ: KYMR)


Kymera Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Kymera Therapeutics Inc 's ROA in the second quarter of 2026?
Kymera Therapeutics Inc recorded a cumulative net loss of $-300 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -19.46%.

However, within the Healthcare sector 355 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3501, from total ROA ranking in the first quarter of 2026 at 4177.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 45.48 % 81.75 % 87.84 % 12.23 % 46.02 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -300 -315 -311 -295 -275
Return On Assets (TTM) -19.46 % -22.32 % -25.45 % -28.94 % -27.83 %
KYMR's Total Ranking # 3501 # 4177 # 3731 # 3727 # 3759
Total Assets (TTM) in million 1,645 1,669 1,743 1,102 1,131
Seq. Total Assets Change -1.41 % -4.23 % 58.14 % -2.57 % 23.17 %
Seq. Net Income Change - - - - -

KYMR's 5 Years Annual ROA >> Back to KYMR Management Effectiveness >> Compare KYMR ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 35
Sector # 356
Overall # 3410

Return On Assets Statistics
High Average Low
-7.97 %
-23.19 %
-28.59 %
(Jun 30 2021)   (Sep 30 2025)



  News about Kymera Therapeutics Inc Return on Assets ROA

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

Kymera Therapeutics: Pioneering a New Era in Oral Immunology Amidst Financial ChallengesOverview of Facts:1. Recent FDA Clearance: Kymera Therapeutics received FDA clearance for its Investigational New Drug (IND) application for KT-621, marking a significant milestone as the first oral STAT6 degrader targeting Th2-mediated diseases. 2. Clinical Development: The Phase 1 trial for KT-621 is currently ongoing with results anticipated in the second quarter of 2025. This trial involves healthy volunteers and aims to assess the safety and pharmacokinetics of the drug.3. Financial Performance: The company reported a cumulative net loss of $167 million over the 12 months ending in Q3 2024, leading to a negative return on assets (ROA) of -21.68%. This financial performance raises concerns regarding the sustainability and viability of its projects.



Financial Statements
Kymera Therapeutics Inc 's Assets $ 1,645 million KYMR's Balance sheet
Kymera Therapeutics Inc 's Income $ -61 million Quarterly KYMR's Income Statement
KYMR's Income by Division See KYMR's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 171.23 % 78.63 % -75.8 % 27.24 % 252.04 %
Total Assets in million 2,514 927 519 2,144 1,685
Y / Y Net Income Change - - - - -
Net Income in million -311 -224 -147 -155 -100
Annual Return On Assets -12.38 % -24.15 % -28.32 % -7.22 % -5.95 %

KYMR's 5 Years Annual ROA >> Back to KYMR Management Effectiveness >> Compare KYMR ROA to its Competitors



More Return On Assets Ratios
KYMR's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
KYMR's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for KYMR's Competitors
Subscribers only: Roa for Kymera Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for KYMR's Customers

You may also want to know
KYMR's Roi KYMR's Inventory Turnover Ratio KYMR's Growth Rates KYMR's Dividend Comparisons
KYMR's Profitability Ratios KYMR's Asset Turnover Ratio KYMR's Dividend Growth
KYMR's Roe KYMR's Valuation Ratios KYMR's Financial Strength Ratios KYMR's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA

Date modified: 2026-09-11T10:03:12+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.